Back to Search Start Over

Diagnostic accuracy of a novel and rapid lipoarabinomannan test for diagnosing tuberculosis among people with human immunodeficiency virus

Authors :
Tobias Broger
Samuel G Schumacher
Stephanie Bjerrum
Maunank Shah
Aurélien Macé
Claudia M. Denkinger
Rita Székely
Isik Somuncu Johansen
Satoshi Mitarai
Margaret Lartey
Kinuyo Chikamatsu
Kennedy Kwasi Addo
Japheth A Opintan
Ernest Kenu
Emmanuel Moreau
Source :
Bjerrum, S, Broger, T, Székely, R, Mitarai, S, Opintan, J A, Kenu, E, Lartey, M, Addo, K K, Chikamatsu, K, Macé, A, Schumacher, S G, Moreau, E, Shah, M, Johansen, I S & Denkinger, C M 2020, ' Diagnostic accuracy of a novel and rapid lipoarabinomannan test for diagnosing tuberculosis among people with human immunodeficiency virus ', Open Forum Infectious Diseases, vol. 7, no. 1, ofz530 . https://doi.org/10.1093/ofid/ofz530, Open Forum Infectious Diseases
Publication Year :
2020

Abstract

Background The novel Fujifilm SILVAMP TB-LAM (FujiLAM) assay detects mycobacterial lipoarabinomannan in urine and has demonstrated superior sensitivity to the Alere Determine TB-LAM Ag (AlereLAM) assay for detection of tuberculosis among hospitalized people with human immunodeficiency virus (PWH). This is the first study to evaluate the assay among a broad population referred for antiretroviral therapy including both outpatients (mainly) and inpatients. Methods We assessed diagnostic accuracy of FujiLAM and AlereLAM assays in biobanked urine samples from a cohort of adults referred for antiretroviral therapy in Ghana against a microbiological and a composite (including clinical judgement) reference standard, and we assessed the association of FujiLAM test positivity with mortality. Results We evaluated urine samples from 532 PWH (462 outpatients, 70 inpatients). Against a microbiological reference standard, the sensitivity of FujiLAM was 74.2% (95% confidence interval [CI], 62.0–84.2) compared to 53.0% (95% CI, 40.3–65.4) for AlereLAM, a difference of 21.2% (CI, 13.1–32.5). Specificity was 89.3% (95% CI, 85.8–92.2) versus 95.6% (95% CI, 93.0–97.4) for FujiLAM and AlereLAM, a difference of −6.3% (95% CI −9.6 to −3.3). Specificity estimates for FujiLAM increased markedly to 98.8% (95% CI, 96.6–99.8) in patients with CD4 >100 cells/µL and when using a composite reference standard. FujiLAM test positivity was associated with increased cumulative risk of mortality at 6 months (hazard ratio, 4.80; 95% CI, 3.01–7.64). Conclusions FujiLAM offers significantly increased diagnostic sensitivity in comparison to AlereLAM. Specificity estimates for FujiLAM were lower than for AlereLAM but were affected by the limited ability of the reference standard to correctly diagnose tuberculosis in individuals with low CD4 counts.<br />Diagnosis of HIV-associated tuberculosis remains a major challenge. The novel rapid Fujifilm SILVAMP TB-LAM urinary assay demonstrated significantly higher sensitivity than Alere Determine TB-LAM for diagnosing tuberculosis among people with HIV among outpatients and across CD4 cell count strata.

Details

Language :
English
Database :
OpenAIRE
Journal :
Bjerrum, S, Broger, T, Székely, R, Mitarai, S, Opintan, J A, Kenu, E, Lartey, M, Addo, K K, Chikamatsu, K, Macé, A, Schumacher, S G, Moreau, E, Shah, M, Johansen, I S & Denkinger, C M 2020, ' Diagnostic accuracy of a novel and rapid lipoarabinomannan test for diagnosing tuberculosis among people with human immunodeficiency virus ', Open Forum Infectious Diseases, vol. 7, no. 1, ofz530 . https://doi.org/10.1093/ofid/ofz530, Open Forum Infectious Diseases
Accession number :
edsair.doi.dedup.....e83e5cbc36e3bd15fc1536523b170206
Full Text :
https://doi.org/10.1093/ofid/ofz530